Your browser doesn't support javascript.
loading
Identifying targetable metabolic dependencies across colorectal cancer progression.
Legge, Danny N; Collard, Tracey J; Stanko, Ewelina; Hoskin, Ashley J; Holt, Amy K; Bull, Caroline J; Kollareddy, Madhu; Bellamy, Jake; Groves, Sarah; Ma, Eric H; Hazelwood, Emma; Qualtrough, David; Amulic, Borko; Malik, Karim; Williams, Ann C; Jones, Nicholas; Vincent, Emma E.
Afiliação
  • Legge DN; School of Translational Health Sciences, Dorothy Hodgkin Building, University of Bristol, Bristol, BS1 3NY, UK.
  • Collard TJ; School of Cellular & Molecular Medicine, University of Bristol, UK.
  • Stanko E; School of Translational Health Sciences, Dorothy Hodgkin Building, University of Bristol, Bristol, BS1 3NY, UK.
  • Hoskin AJ; School of Cellular & Molecular Medicine, University of Bristol, UK.
  • Holt AK; School of Cellular & Molecular Medicine, University of Bristol, UK.
  • Bull CJ; School of Translational Health Sciences, Dorothy Hodgkin Building, University of Bristol, Bristol, BS1 3NY, UK; Integrative Epidemiology Unit, School of Population Health Science, University of Bristol, UK.
  • Kollareddy M; School of Biochemistry, University of Bristol, UK.
  • Bellamy J; School of Cellular & Molecular Medicine, University of Bristol, UK.
  • Groves S; School of Cellular & Molecular Medicine, University of Bristol, UK.
  • Ma EH; Metabolic and Nutritional Programming, Center for Cancer and Cell Biology, Van Andel Institute, UK.
  • Hazelwood E; School of Translational Health Sciences, Dorothy Hodgkin Building, University of Bristol, Bristol, BS1 3NY, UK; Integrative Epidemiology Unit, School of Population Health Science, University of Bristol, UK.
  • Qualtrough D; Faculty of Health and Life Sciences, University of the West of England, UK.
  • Amulic B; School of Cellular & Molecular Medicine, University of Bristol, UK.
  • Malik K; School of Cellular & Molecular Medicine, University of Bristol, UK.
  • Williams AC; School of Cellular & Molecular Medicine, University of Bristol, UK.
  • Jones N; Institute of Life Science, Swansea University Medical School, Swansea University, SA2 8PP, UK.
  • Vincent EE; School of Translational Health Sciences, Dorothy Hodgkin Building, University of Bristol, Bristol, BS1 3NY, UK; Integrative Epidemiology Unit, School of Population Health Science, University of Bristol, UK. Electronic address: emma.vincent@bristol.ac.uk.
Mol Metab ; : 102037, 2024 Sep 26.
Article em En | MEDLINE | ID: mdl-39332495
ABSTRACT
Colorectal cancer (CRC) is a multi-stage process initiated through the formation of a benign adenoma, progressing to an invasive carcinoma and finally metastatic spread. Tumour cells must adapt their metabolism to support the energetic and biosynthetic demands associated with disease progression. As such, targeting cancer cell metabolism is a promising therapeutic avenue in CRC. However, to identify tractable nodes of metabolic vulnerability specific to CRC stage, we must understand how metabolism changes during CRC development. Here, we use a unique model system - comprising human early adenoma to late adenocarcinoma. We show that adenoma cells transition to elevated glycolysis at the early stages of tumour progression but maintain oxidative metabolism. Progressed adenocarcinoma cells rely more on glutamine-derived carbon to fuel the TCA cycle, whereas glycolysis and TCA cycle activity remain tightly coupled in early adenoma cells. Adenocarcinoma cells are more flexible with respect to fuel source, enabling them to proliferate in nutrient-poor environments. Despite this plasticity, we identify asparagine (ASN) synthesis as a node of metabolic vulnerability in late-stage adenocarcinoma cells. We show that loss of asparagine synthetase (ASNS) blocks their proliferation, whereas early adenoma cells are largely resistant to ASN deprivation. Mechanistically, we show that late-stage adenocarcinoma cells are dependent on ASNS to support mTORC1 signalling and maximal glycolytic and oxidative capacity. Resistance to ASNS loss in early adenoma cells is likely due to a feedback loop, absent in late-stage cells, allowing them to sense and regulate ASN levels and supplement ASN by autophagy. Together, our study defines metabolic changes during CRC development and highlights ASN synthesis as a targetable metabolic vulnerability in later stage disease.
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2024 Tipo de documento: Article